Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows MDRNA Patent on Peptides for Delivery to Lung

Premium

MDRNA said this week that the US Patent and Trademark Office has allowed a company patent application covering "methods for the delivery of a broad array of compounds with pharmacological activity, including siRNAs, using proprietary targeting peptides that have preferential binding affinity for lung tissue."

The application, No. 20070197444, is entitled, "Phage-Displayed Cell-Binding Peptides," and claims "a tryptophan cage-binding domain polypeptide containing of all or part of [a defined] amino acid sequence," according to its abstract.

"This technology is directly applicable to the company's DiLA2 [drug-delivery] platform as peptides are readily conjugated to the amino acid scaffold of a DiLA2" molecule, MDRNA said. "Peptides capable of directed delivery are expected to further improve the delivery efficiency of UsiRNAs, which have demonstrated significant knockdown of target genes in mouse models of liver and bladder cancer, and in non-human primates."

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.